NCT01887964

Brief Summary

Metabolic syndrome is a condition characterized by excess body weight, large waist circumference, high cholesterol and glucose in the blood, and hypertension. People with metabolic syndrome are at increased risk for heart diseases. Research shows benefits of regular fiber intake in metabolic syndrome. However, due to altered taste and texture of the high fiber foods, long term intake of fiber is a challenge for metabolic syndrome patients. This study is designed to find if blinded-substitution of regular wheat flour in domestic kitchen with wheat flour enriched by an adaptable type of fiber (resistant starch-4), minimizes metabolic syndrome symptoms. this special type of fiber is also obtained from wheat.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
86

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2012

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2012

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2012

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

June 20, 2013

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 27, 2013

Completed
Last Updated

September 27, 2021

Status Verified

September 1, 2021

Enrollment Period

7 months

First QC Date

June 20, 2013

Last Update Submit

September 21, 2021

Conditions

Keywords

DiabetesObesityCardiovascular diseaseMetabolic syndrome

Outcome Measures

Primary Outcomes (1)

  • Changes in metabolic syndrome risk components

    26 weeks

Secondary Outcomes (3)

  • Changes in anthropometric outcomes

    26 weeks

  • Changes in blood lipid profile

    26 weeks

  • Changes in blood glucose indices

    26 weeks

Study Arms (2)

Community-1

OTHER

Received control flour first and then Resistant starch type 4 (RS4) flour

Other: RS4 enriched flourOther: Control flour

Community-2

OTHER

Received RS4 flour first and then control flour

Other: RS4 enriched flourOther: Control flour

Interventions

Wheat flour with 30% resistant starch (type-4)

Community-1Community-2

Wheat flour without resistant starch (type-4)

Community-1Community-2

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \- Any individual aged 18-80 years

You may not qualify if:

  • Pregnant
  • Lactating
  • Requires special diets or dietary regimens
  • On long term antibiotic therapy
  • Diagnosed with gastrointestinal diseases (Irritable Bowel syndrome, Crohn's disease or Colitis)
  • Immune compromised
  • Have cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

South Dakota State University

Brookings, South Dakota, 57007, United States

Location

Related Publications (1)

  • Dhakal S, Dey M. Resistant starch type-4 intake alters circulating bile acids in human subjects. Front Nutr. 2022 Oct 20;9:930414. doi: 10.3389/fnut.2022.930414. eCollection 2022.

MeSH Terms

Conditions

Metabolic SyndromeDiabetes MellitusObesityCardiovascular Diseases

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Moul Dey, PhD

    South Dakota State University

    PRINCIPAL INVESTIGATOR
  • Bonny Specker, PhD

    South Dakota State University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

June 20, 2013

First Posted

June 27, 2013

Study Start

March 1, 2012

Primary Completion

October 1, 2012

Study Completion

October 1, 2012

Last Updated

September 27, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will not share

Individual participant's identity will not be shared. This clinical trial is complete. All results were published as two research articles: PMCID: PMC4928084 and PMCID: PMC4048643. Raw sequence data were submitted to Sequence Read archive as referenced in the manuscript PMC4928084.

Locations